Products
PRIMARY ANTIBODY
SECONDARY ANTIBODY
PROTEIN & PEPTIDES
BIOCHEMICALS
ASSAY & ELISA KITS
LOADING CONTROL
OTHER REAGENTS
SERUMS
CELL LINE
Contact Us
About Us
Login
Register
|
Forgot Password
Sign In
Forgot your Password?
If you've forgotten your password, enter your e-mail address below and we'll send you instructions on how to securely change your password.
Back
Continue
0
Shopping Cart
Products
Contact Us
About Us
Shopping Cart
Loading....
Login Account
Sign In
Register
Register
|
Forgot Password
Sign In
Forgot your Password?
If you've forgotten your password, enter your e-mail address below and we'll send you instructions on how to securely change your password.
Back
Continue
0
Shopping Cart
Home
BioChemicals
MGCD-265 analog
tcsc0188
MGCD-265 analog
Order Now
AVAILABLE SIZES
2mg
5mg
10mg
50mg
$
137.00
Add to Cart
ORDERING INFORMATION
International
TAICLONE BIOTECH CORP.
order@taiclone.com
+886-2-2735-9682
+886-2-2735-9807
Data sheet
Download PDF Datasheet
Technical Inquries
Submit Review
Submit Review
Please choose your application, enter the information requested below. * Marked fields are mandatory.
Full Name
Email
Contact Number
Application
Please Select..
Western blot (WB)
Immunohistochemistry (IHC)
Immunofluorescence (IF)
Immunocytochemistry (ICC)
Immunoprecipitation (IP)
Co-Immunoprecipitation (CoIP)
Chromatin Immunoprecipitation (ChIP)
RNA Binding Protein Immunoprecipitation (RIP)
Sample
Loading Amount
Loading Type
UG
CELLS
Treatment
Temperature
Exposure
Observe Band
Fixative
Select One
Acetone
Formaldehyde
Methanol
Paraformaldehyde
Other
Antigen Retrieval
Select One
Heat mediated
Enzymatic
Other
None
Positive Control
Negative Control
Dilution *
1:
Incubation Time *
Select Image *
Choose a file...
Rating *
Remarks *
Submit Review
Product Description
MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitargeted tyrosine kinase inhibitor with potential antineoplastic activity with IC50 of 29 nM and 10 nM for c-Met and VEGFR2, respectively.
IC50 value:10 nM (VEGFR2), 29 nM(c-Met) [1]
Target:VEGFR, c-Met
in vivo: MGCD-265-analog has a reasonable half-life, 1.2 h in rats and 5.8 h in dogs, and has an acceptable clearance, 0.33 L/(kg h) in rats and 1.1 L/(kg h) in dogs. The steady state volume of distribution was low in rats (0.25 L/kg) and reasonable in dogs (1.5 L/kg), while the oral bio-availability was determined to be 12% and 42% in rats and dogs, respectively. GCD-265-analog performed well in vivo against a panel of different human tumor types, particularly those that are driven by or overexpress c-Met (MNNGHOS and MKN45). Tumor growth inhibition at a dose of 20 mg/kg po once daily ranged from 41% to 94%. MGCD-265-analog was found to show spill-over inhibition of a number of kinases in addition to the intended c-Met/VEGFR2 activity. MGCD-265-analog has significant antitumor activity in vivo.[1]
Information
CAS No
875337-44-3
Formula
C
26
H
20
FN
5
O
2
S
2
Clinical Information
clinicalinformation
Pathway
Protein Tyrosine Kinase/RTK
Protein Tyrosine Kinase/RTK
Target
c-Met/HGFR
VEGFR
Specifications
Purity / Grade
>98%
Solubility
10 mM in DMSO
Smiles
smiles
Misc Information
Observed Molecular Weight
517.6
related data
Get valuable resources and offers directly to your email.
REGISTER NOW